Bottom line
Is TBXU a good fund? The bottom line
TBXU is a managed leveraged & inverse ETF from Direxion.
Annual fees run 0.98% — about $98 a year on every $10,000 invested, cheaper than 76% of leveraged & inverse funds we track.
With $2.6 million in net assets and 10 holdings, its largest position is Goldman Financial (29.4%) and the top 10 make up 100.1% of the portfolio.
What stands out
- Low cost: cheaper than 76% of leveraged & inverse peers
What to watch
- Concentrated: top 10 holdings are 100.1% of assets
- Small fund ($2.6 million) — small funds are likelier to close
Updated Nov 19, 2026
What TBXU invests in
The Fund seeks daily investment results, before fees and expenses, of 200% of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
"The Index consists of the top five securities in the NYSE Biotechnology Index, which includes U.S.-listed companies in the biotechnology sub-industry as classified by the Global Industry Classification Standards (GICS). ICE Data Indices, LLC (the Index Provider) selects the top five securities of the NYSE Biotechnology Index based on each securitys total market capitalization. The Index is equal weighted, meaning that at each rebalancing of the Index, the same exposure is provided to each security included in the Index. The Index is rebalanced and reconstituted quarterly. As of December 31, 2025, the Index had five constituents, which were concentrated in the biotechnology industry, which is part of the healthcare sector. The Fund, under normal circumstances, invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, securities of the…
From the fund's prospectus (filed Mar 3, 2026).
What TBXU costs
On a $10,000 investment, TBXU's 0.98% expense ratio costs about $98 a year. The prospectus estimates $5,645 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
TBXU top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Goldman Financial | 29.36% |
| 2 | Dreyfus | 21.64% |
| 3 | Regeneron Pharmaceuticals Inc REGN | 9.09% |
| 4 | Amgen Inc AMGN | 7.95% |
| 5 | Vertex Pharmaceuticals Inc VRTX | 7.84% |
| 6 | Gilead Sciences Inc GILD | 7.58% |
| 7 | Argenx Se - Adr ARGX | 6.98% |
| 8 | Goldman Sachs Liq Es Fd A | 6.23% |
| 9 | N/a | 2.83% |
| 10 | N/a | 0.62% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 100.1% of the fund. See all top 25 holdings and asset mix →